<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimicrobial therapy for treatment of South American bartonellosis*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimicrobial therapy for treatment of South American bartonellosis*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antimicrobial therapy for treatment of South American bartonellosis*</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Stage</td> <td class="subtitle1">Drug</td> <td class="subtitle1">Notes</td> <td class="subtitle1">Adult dose</td> <td class="subtitle1">Pediatric dose</td> </tr> <tr> <td class="divider_bottom" rowspan="4">Oroya fever<br/> (Carrion's disease)</td> <td>Ciprofloxacin</td> <td>Treatment of choice for uncomplicated Oroya fever in adults.</td> <td>500 mg orally twice daily for 14 days</td> <td>20 mg/kg orally in two divided doses for 14 days (max 1 g/day)<sup>¶</sup></td> </tr> <tr> <td>Chloramphenicol</td> <td>Alternative treatment choice for treatment of Oroya fever; recurrence has been described. Administered in combination with ceftriaxone.</td> <td> <p>50 to 75 mg/kg/day (up to 3 g/day) orally or intravenously in four divided doses for 10 to 14 days</p> Following defervescence, may be reduced to 25 mg/kg orally or intravenously in four divided doses</td> <td> <p>50 to 75 mg/kg/day (up to 2 g/day) orally or intravenously in four divided doses for 10 to 14 days<sup>¶</sup></p> Following defervescence, may be reduced to 25 mg/kg orally or intravenously in four divided doses</td> </tr> <tr> <td>Ceftriaxone</td> <td> <p>Administered in combination with chloramphenicol.</p> Administered in combination with ciprofloxacin for treatment of severe disease.</td> <td>1 g intravenously once daily for 10 to 14 days</td> <td>50 to 75 mg/kg intravenously once daily for 10 to 14 days (maximum 1 g/day)</td> </tr> <tr class="divider_bottom"> <td>Amoxicillin-clavulanic acid</td> <td>Treatment of choice for uncomplicated Oroya fever in children and pregnant women.</td> <td>1 g (based on amoxicillin) orally twice daily for 14 days</td> <td>40 mg/kg (based on amoxicillin) orally in three divided doses for 14 days (maximum 2 g/day)</td> </tr> <tr> <td rowspan="3">Verruga peruana<br/> (Peruvian wart)</td> <td>Azithromycin</td> <td>Treatment of choice in adults, children, and pregnant women.</td> <td>500 mg orally once daily for 7 days</td> <td>10 mg/kg orally once daily for 7 days (maximum 500 mg/day)</td> </tr> <tr> <td>Rifampin</td> <td>Treatment failures have been reported; alternate treatment choice.</td> <td>600 mg orally once daily for 14 to 21 days</td> <td>10 mg/kg orally once daily for 14 to 21 days (maximum 600 mg/day)</td> </tr> <tr> <td>Ciprofloxacin</td> <td>Alternate treatment choice.</td> <td>500 mg orally twice daily for 7 to 10 days</td> <td>20 mg/kg orally in two divided doses for 14 days (max 1 g/day)<sup>Δ</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">Refer to Lexicomp drug monographs for further information.</div><div class="graphic_footnotes">* See text for discussion of approach to antibiotic selection.<br/>¶ Chloramphenicol may cause bone marrow depression and aplastic anemia; dose adjustments are required for renal or hepatic impairment. Optimally, serum concentration should be monitored if chloramphenicol is employed. The risk of toxicity due to chloramphenicol may exceed that of ciprofloxacin.<br/>Δ Ciprofloxacin is not a drug of first choice in children due to reported adverse events related to joints and/or surrounding tissues. In some pediatric studies, an increased risk of reversible adverse events involving joints or surrounding tissues, often due to reports of arthralgia, has been observed. However, no compelling published evidence supports the occurrence of sustained injury to developing bones or joints in children treated with available fluoroquinolone agents<sup>[1]</sup>. The risks and benefits should be considered if a fluoroquinolone is prescribed in a child younger than 18 years of age.</div><div class="graphic_reference">Reference:

<ol>
<li>Bradley JS, Jackson MA, Committee on Infectious Diseases, American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 2011; 128:e1034.</li>
</ol></div><div id="graphicVersion">Graphic 77298 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
